Militia Long/Short Equity ETF
Limited financial coverage for ORR.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The Militia Long/Short Equity ETF, identified by the symbol ORR, is an actively managed investment vehicle designed to achieve capital appreciation. It employs a dual strategy, taking both long and short positions in equities. For its long-term holdings, the fund primarily focuses on stocks in developed markets that are either deemed undervalued or possess substantial growth potential.
- IPO
- 2025
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on ORR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $39.80
- 52W Low
- $30.66
- 50D MA
- $37.29
- 200D MA
- $36.06
- Beta
- 0.03
- RSI (14)
- 52
- Avg Volume
- 95.17K
No earnings-call transcripts are available for ORR yet.
- Free Float
- 0.0%
- Shares Outstanding
- 973.43K
- Float Shares
- 0
of shares held by institutions
14 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Militia Capital Partners, LP | 161.00K | ▲ 38.00K |
Our ORR coverage
Recent articles, reports, and earnings notes.
No research on ORR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORR report →Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
gurufocus.com · Jul 23
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
gurufocus.com · Jun 13
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
gurufocus.com · Jun 13
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
gurufocus.com · Jun 11
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
gurufocus.com · Jun 1
ORR: A Long/Short Hedge Fund Disguised As An ETF
seekingalpha.com · Jun 1
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
gurufocus.com · May 31
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
gurufocus.com · May 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.